In the last decades, increased interest in imaging of elements/metals/proteins distribution, mainly in pharmaceutical, biomedicine research, or life science with direct application of research to specific problem/disease [1-3]. As WHO data indicates, cerebrovascular events are one of the main causes of mortality in developed nations. The key to success is time (as short as possible). Biodegradable iodinated nanoparticles (IoNPs) could be an invaluable addition to the existing contrast agents used in medicine. A complete investigation into the pharmacokinetics and dynamics of Ion-based Nanoparticles (IoNPs) is essential to address this issue. With the combination of CT and LA-ICP-MS imaging, this comprehensive evaluation verifies the treatment strategy's overall success, positioning LA-ICP-MS as a potential "gold standard" imaging method for researching and applying IoNPs in theranostics. Nowadays, LA-ICP-MS is also starting to be used as a technique for the simultaneous specific determination of the protein of interest, which opens up the possibility of achieving the so-called multiplex analysis. Protein determination, protein imaging and finally their distribution in clinical samples are presented. Proteins are imaged using an immunohistochemical method (binding nanoparticle-labeled antibodies to a specific protein) and LA-ICP-MS. The main advantages of utilizing LA-ICP-MS are the acquisition of comprehensive (Metallo)proteomic information about the tissue of a given disease (in this case, cancer or stroke) or low detection limits compared to other conventionally employed protein imaging techniques in combination with multiplex analysis of one sample.